# Diabetes Research Hub — Monitor Report

**Run date:** 2026-07-25 (automated review run)
**Prepared by:** Hub Monitor (scheduled task)
**Scope:** Read-only review of `Analysis/Results/` outputs + web scan. No existing files modified.

---

## TL;DR — The thing you don't want to hear

**Day 8 of the fetch freeze. This is now a broken pipeline, not a stale one — stop treating it as a passive "flag" and go fix the two scripts.** `clinical_trials_latest.json` and `pubmed_recent_latest.json` are still stuck at **2026-07-17** (8 days old). Five consecutive monitor runs (07-21 → 07-25) have now flagged the identical staleness with the identical numbers. The trial JSON is byte-for-byte the 07-17 corpus: 858 trials, 52 Phase-3 recruiting, 12 cross-domain PubMed papers — I re-derived all three directly from the files, not from the prior report, and they are unchanged. **Any "no change" this monitor reports on the trial/PubMed arm is an artifact of the fetch never running, not a real signal.** [Certain — file mtimes + re-derived counts confirm identical data]

What *is* alive: the literature/gap/evidence arm fully refreshed on 07-24 (`literature_gap_report.md`, `gap_evidence.json`, `evidence_network.json`, `citation_validation.json`, `pmid_verification.json` all re-ran). So the failure is now cleanly isolated to exactly **two baseline fetch scripts** — everything else in the hub is running daily.

The single action that matters this week is unchanged from 07-21: run `baseline_clinical_trials.py` and `baseline_pubmed_alerts.py`, then find out why they've been silently dead for 8 days.

---

## File System Status

| File | Last modified | Age | Status |
|------|---------------|-----|--------|
| `clinical_trials_latest.json` | 2026-07-17 | 8 days | ⚠️ Stale |
| `pubmed_recent_latest.json` | 2026-07-17 | 8 days | ⚠️ Stale |
| `hub_monitor_report.md` | 2026-07-17 | 8 days | ⚠️ Stale (no scan since 07-17) |
| `literature_gap_report.md` | 2026-07-24 | 1 day | ✅ Fresh (re-ran since last monitor) |
| `literature_gap_data.json` | 2026-07-18 | 7 days | ◐ Aging |
| `Diabetes_Research_Tracker.xlsx` | 2026-07-17 | 8 days | ◐ Aging |
| Latest trial snapshot | `..._2026-07-17.json` | 8 days | ⚠️ No snapshot since 07-17 |
| Latest PubMed snapshot | `..._2026-07-17.json` | 8 days | ⚠️ No snapshot since 07-17 |
| `agent_state.json` | 2026-07-24 | 1 day | ✅ Daily backups healthy |

**Change since the 07-24 report:** the gap/evidence arm caught up — `gap_evidence.json` and `evidence_network.json` (which were 07-16 last week) both refreshed 07-24, alongside the gap report. That narrows the fault to the two fetch scripts alone. The hub's own review flag still reports **827 result files older than 14 days**. This is a scheduling/cron gap on those two jobs, not a transient miss. [Certain]

---

## Clinical Trial Changes

No fetch since 07-17, so there is **no new trial movement to report**. All figures below are re-derived from the 07-17 snapshot (858 trials), confirmed against the file today.

**Category counts (07-17):** T1D Cure & Cell Therapy 152 · T1D Immunotherapy & Prevention 76 · T2D Novel Therapies (P2–3) 147 · Diabetes Technology 236 · Recently Completed w/ Results 321.

**Phase-3 RECRUITING — priority sponsors (52 P3 recruiting total; re-derived from JSON):**

| NCT | Sponsor | Asset | Status |
|-----|---------|-------|--------|
| NCT06832410 / NCT04786262 | Vertex | zimislecel (VX-880), incl. kidney-transplant cohort | RECRUITING (P3) |
| NCT07222332 / NCT07222137 | Eli Lilly | Baricitinib | RECRUITING (P3) |
| NCT06739122 | Eli Lilly | (Lilly P3, dapagliflozin-class) | RECRUITING (P3) |
| NCT07076199 | Novo Nordisk | Insulin icodec (weekly) in T1D | RECRUITING (P3) |
| NCT07564414 | Novo Nordisk | CagriSema | RECRUITING (P3) |

No Sana Biotechnology trials appear in the priority-sponsor Phase-3 recruiting set in this snapshot.

**Recently posted results, July 2026 (14 total; newest first):** NCT05086445 (Lilly orforglipron PK, Japanese pts, 07-16) · NCT05574699 (JHU social-risk closed-loop referral CDS, 07-15) · NCT05254002 (Bayer finerenone + empagliflozin in CKD/T2D, P2, 07-13) · NCT04717050 (Dana-Farber, metabolic dysregulation in obese Latina, 07-10) · NCT03263494 (Jaeb CGM in teens/young adults T1D, 07-09) · NCT04255433 (Lilly tirzepatide vs dulaglutide CV outcomes, P3, 07-08).

*Every item above was already surfaced in the 07-17 → 07-24 runs. It cannot change until the fetch script runs.* [Certain]

---

## PubMed Highlights

From `pubmed_recent_latest.json` (07-17; 158 unique papers, 30-day lookback, 16 domains, 8 tracked therapies). **12 cross-domain papers** — re-derived from the file today, unchanged. Highest-value:

- **[42459945]** *A framework for assessing algorithmic discrimination risks in training data: pediatric type 1 diabetes* — **3 domains: AI/ML + Closed-Loop AP + Health Equity.** Sits on a Tier-1 axis (AI/ML) crossing an under-researched equity domain. Top single item in the corpus.
- **[42419792]** *Comparative effects of drugs for overweight/obesity (network meta-analysis)* — one analysis spanning **orforglipron + retatrutide + CagriSema** (3 tracked therapies).
- **[42411999]** *Type 1 Diabetes Driven by Residual Recipient T Cells* — Stem-Cell Cure × Immunotherapy (post-HCT case).
- **[42453334]** *Noncoding RNAs from in silico to clinic* — Biomarker × LADA.
- **[42459212]** *Precision nutrition in Asian populations* + **[42458730]** *multi-omic BMI-response modelling* — both Microbiome × Multi-Omics (Tier-1 Multi-Omics axis).
- **[42436543]** / **[42458355]** — two Health-Equity crossovers (T2D remission inequalities; socioeconomic gradients in hypertension via AI/ML).

**Tracked therapies:** all 8 present in the corpus (zimislecel, orforglipron, retatrutide, CagriSema, baricitinib, teplizumab, icodec, dapagliflozin). Watch item carried forward: **zimislecel** has near-zero indexed papers despite two active Vertex P3s — confirm on the next real pull that this isn't a query/terminology artifact.

*Same 07-17 corpus as last week; no newer pull exists.* [Certain]

---

## Gap Analysis Summary

Gap report is **fresh (07-24, re-ran since last monitor)**. Top *potentially meaningful* under-researched intersections (Gap Score 100 = zero joint pubs). **Validation level: BRONZE** — single analytical source, expert confirmation required per doctrine:

1. **Treg / CAR-T × Neuropathy** (0 joint) — immune-mediated diabetic neuropathy as a Treg-modulation target.
2. **Beta Cell Regen × Health Equity** (0) — no equity analysis of access to emerging cell therapies.
3. **Treg / CAR-T × Health Equity** (0) — no access analysis for CAR-Treg/TCR-Treg.
4. **Glucokinase × Health Equity** (0) — no equity work on GK activators.
5. **Gene Therapy × LADA** (0) — LADA's autoimmune mechanism unexplored for gene therapy.

(Also flagged: **Drug Repurposing × Health Equity**, 0 joint; and **Insulin Resistance × Islet Transplant**, Gap 91.9 / 1 joint.)

**Tier-1 alignment (RESEARCH_DOCTRINE.md):** Drug Repurposing × Health Equity maps directly onto the doctrine's Tier-1 **Drug Repurposing** axis; the cross-domain PubMed hits map onto Tier-1 **Multi-Omics** and **AI/ML**. Per doctrine, all gap classifications stay **BRONZE** until triple-source validated — do not elevate without expert sign-off. [Certain — sourced from gap report + doctrine]

---

## Breaking News (web scan, last 7 days)

Nothing new broke in the last 24 hours. The three standing items — all on tracked therapies, none yet in the 07-17 snapshot — remain:

- **Orforglipron (Foundayo) — FDA-approved for chronic weight management** (Q2 2026, first oral small-molecule GLP-1 to market). The **type-2 diabetes** indication is still under FDA review (ATTAIN/ACHIEVE Phase-3 program). [Likely — FDA + Lilly IR + secondary sources]
- **Insulin efsitora alfa (Lilly, once-weekly, QWINT) — FDA decision still PENDING** as of late July 2026; no approval issued yet. QWINT-1/2/3 showed HbA1c reductions non-inferior to daily glargine/degludec. Would compete directly with Novo's already-approved weekly icodec (Awiqli). This resolves the 07-24 "unresolved timing" flag: **still not decided.** [Likely — Prime Therapeutics FDA calendar + Medscape + Lilly IR]
- **Teplizumab (Tzield) — pediatric approval** (Phase-3 PROTECT, ages 8–17, recent-onset stage-3 T1D). Relevant to the Sanofi teplizumab P3 (NCT07088068) and Lilly baricitinib P3s in the tracker. [Likely]

No Phase-3 topline, FDA action, or major publication newer than the 07-24 report was found. [Certain — nothing significant surfaced]

---

## Recommended Actions

Ordered by leverage.

1. **Run the two fetch scripts — this is the entire week's job.**
   `python baseline_clinical_trials.py` and `python baseline_pubmed_alerts.py`, then `python hub_monitor.py` to diff against a real current fetch. Until this runs, every "no change" here is unverified. [Certain]
2. **Diagnose the silent failure.** The gap/evidence/agent loop all run daily; only these two fetch jobs have been dead 8 days. Check the cron/scheduler entry and the scripts' own error logs — 8 days of silence means no alerting is wired to these two jobs specifically. Wire a staleness alert so this can't repeat. [Certain it's the failure; Guessing on root cause]
3. **On the next real fetch, record three regulatory events at correct evidence level:** (a) orforglipron **T2D** indication status, (b) insulin efsitora alfa FDA decision (still pending), (c) teplizumab pediatric label. All touch tracked assets. [Likely relevant]
4. **Read cross-domain paper [42459945]** (AI/ML × Closed-Loop × Health Equity, pediatric T1D algorithmic-discrimination framework) — Tier-1 axis intersecting a top gap. Highest-value single item in the current corpus. [Likely]
5. **Confirm the zimislecel publication gap** on the next PubMed pull — verify near-zero indexing isn't a terminology artifact vs. two active Vertex P3s. [Likely]
6. **Gap classifications stay BRONZE.** Submit the top-5 intersections (esp. Drug Repurposing × Health Equity → Tier-1) to domain review before elevating. [Certain — per doctrine]

---

*Generated by Diabetes Research Hub Monitor — automated run 2026-07-25. Read-only; no source files modified. Evidence levels per RESEARCH_DOCTRINE.md v1.0.*
